The recombinant KLK10 doses injected IP lead to plasma concentrations orders of magnitude higher at one hour (Fig. 4A) than the highest doses recorded in KLK10 tumour-bearing mice (Table 3), albeit transiently. The gene discussed is KLK10; the disease is neoplasm.